CD19x22 CAR T Cell Therapy (University Of Colorado Denver)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD19x22 CAR T Cell Therapy (University Of Colorado Denver)
Drug Alias NameBispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Colorado, Denver, Usa
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado, Denver, UsaUniversity Of Colorado Denver
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A